These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 14563968)

  • 1. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting.
    Kopp CW; Steiner S; Nasel C; Seidinger D; Mlekusch I; Lang W; Bartok A; Ahmadi R; Minar E
    Stroke; 2003 Nov; 34(11):2560-7. PubMed ID: 14563968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab.
    Qureshi AI; Suri MF; Ali Z; Kim SH; Lanzino G; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2002 Mar; 50(3):466-73; discussion 473-5. PubMed ID: 11841713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy.
    Kapadia SR; Bajzer CT; Ziada KM; Bhatt DL; Wazni OM; Silver MJ; Beven EG; Ouriel K; Yadav JS
    Stroke; 2001 Oct; 32(10):2328-32. PubMed ID: 11588321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S; Seidinger D; Huber K; Kaun C; Minar E; Kopp CW
    Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1697-702. PubMed ID: 12869353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
    Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting: a randomized study.
    Hofmann R; Kerschner K; Steinwender C; Kypta A; Bibl D; Leisch F
    Stroke; 2002 Mar; 33(3):725-7. PubMed ID: 11872895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracarotid abciximab injection to abort impending ischemic stroke during carotid angioplasty.
    Ho DS; Wang Y; Chui M; Wang Y; Ho SL; Cheung RT
    Cerebrovasc Dis; 2001; 11(4):300-4. PubMed ID: 11385208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
    Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ;
    Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.
    Neumann FJ; Zohlnhöfer D; Fakhoury L; Ott I; Gawaz M; Schömig A
    J Am Coll Cardiol; 1999 Nov; 34(5):1420-6. PubMed ID: 10551687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial comment--Utility of abciximab during carotid stenting when distal protection is contraindicated.
    Levy EI; Hopkins LN
    Stroke; 2003 Nov; 34(11):2567. PubMed ID: 14576366
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy.
    Kanjwal K; Cooper CJ; Virmani R; Haller S; Shapiro JI; Burket MW; Steffes M; Brewster P; Zhang H; Colyer WR
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):16-23. PubMed ID: 20209644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results.
    Schneiderman J; Morag B; Gerniak A; Rimon U; Varon D; Seligsohn U; Shotan A; Adar R
    J Endovasc Ther; 2000 Aug; 7(4):263-72. PubMed ID: 10958289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.